LMAT LeMaitre Vascular, Inc.
USHealthcareAs of 2026-07-10 11:06
Why LMAT matters now
LeMaitre Vascular, Inc. (LMAT) is a US stock in Healthcare. The latest InvestLog snapshot shows $101.50 with -0.88% on the session and $2.32B in market capitalization; recent performance reads 1-month -7.28% and YTD +15.84%.
The latest financial table shown here is Q1 2026, with revenue of $66.6M, net income of $15.7M, and EPS of $0.68. Investors can compare that operating picture with valuation signals such as P/E 45.22 and FCF yield 3.7%.
The latest indexable market news headline is "We Have A Valuation Problem - May Dividend Income Report" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $127.50; recent insider activity includes Kamke Trent G filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
45.22
PEG
1.45
P/B
5.27
P/S
8.38
EV/EBITDA
23.99
DCF Value
$104.72
FCF Yield
3.7%
Div Yield
1.0%
Margins & Returns
Gross Margin
72.4%
Operating Margin
28.5%
Net Margin
24.3%
ROE
16.2%
ROA
9.9%
ROIC
9.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $66.6M | $15.7M | $0.68 |
| Q4 2025 | $64.5M | $15.6M | $0.68 |
| FY 2025 | $249.6M | $57.7M | $2.52 |
| Q3 2025 | $61.0M | $17.4M | $0.75 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$127.50
Target (Median)
$127.50
Target Range
$120.00 - $135.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.52
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.